Screener
Summit Therapeutics SMMT Business Segments — Other income, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Oncology clinical trial related costs | $90,195 | $36,363 |
| Compensation related costs, excluding stock-based compensation | 26,432 | 15,854 |
| Stock-based compensation | 72,791 | 11,096 |
| Other expenses (1) | 5,794 | 3,538 |
| Total segment expenses | 195,212 | 66,851 |
| Other income, net | 5,788 | 3,938 |
| Net loss | $(189,424) | $(62,913) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's business segments — other income, net?
- Summit Therapeutics (SMMT) reported business segments — other income, net of $5.79M in Q1 2026.
- How has Summit Therapeutics's business segments — other income, net changed year-over-year?
- Summit Therapeutics's business segments — other income, net increased by 47.0% year-over-year, from $3.94M to $5.79M.
- What is the long-term trend for Summit Therapeutics's business segments — other income, net?
- Over 3 years (2022 to 2025), Summit Therapeutics's business segments — other income, net has grown at a 86.4% compound annual growth rate (CAGR), from -$2.29M to $14.84M.
- What does business segments — other income, net mean?
- Includes non-operating income streams such as interest income, gains from asset sales, or other miscellaneous financial gains. This metric isolates income generated outside of the segment's core pharmaceutical development operations.
Ask your AI about Summit Therapeutics's business segments — other income, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude